Arovella Therapeutics


Arovella Therapeutics Ltd (Arovella), based in Australia and the US, is a world leader in reformulating and delivering medication through the oral mucosa.

Patients typically take medication as pills, tablets or capsules yet less than 25% of the medication is absorbed into the bloodstream.

Arovella can increase the bioavailability of administered medications, which means it increases the amount of the drug absorbed by the body so is able to increase the effect of that drug.

Arovella has increased bioavailability up to 95%. This is a major step forward in the evolution of drug delivery technology.

Latest Media Releases

Arovella Therapeutics - SPP Offer Booklet

24/01/2022 10:31:00

On behalf of the board of Arovella Therapeutics Limited ACN 090 987 250 (ASX: ALA) (ALA or Company), we are pleased to offer you the opportunity to purchase up to $30,000 in additional shares in ALA…

Arovella Therapeutics - Trading Halt

20/01/2022 09:32:00

The securities of Arovella Therapeutics Limited (‘ALA’) will be placed in trading halt at the request of ALA, pending it releasing an announcement. Unless ASX decides otherwise, the secu…

Latest News